Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimisation

被引:124
作者
AliAbadi, FS [1 ]
Lees, P [1 ]
机构
[1] Univ London Royal Vet Coll, Dept Vet Basic Sci, Hatfield AL9 6TA, Herts, England
关键词
antimicrobial drugs; dosage schedule; pharmacokinetics; pharmacodynamics; pharmacokinetics-pharmacodynamics integation;
D O I
10.1016/S0924-8579(00)00142-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Concern regarding antimicrobial resistance has led to proposals for the prudent use of antimicrobial agents. Whilst this is appropriate, it is not sufficient. This article proposes that dosage schedules should be developed to provide a basis for the rational use of antimicrobial drugs. This requires knowledge of resistance mechanisms and transfer, the biochemistry and structure of microorganisms and both the pharmacodynamics and pharmacokinetics of antimicrobial drugs. Dosage schedules should maintain concentrations at the site of infection in excess of MIG,, for bacteriostatic drugs and bactericidal drugs acting primarily by time-dependent mechanisms whilst they should provide high AUIC and C(max/)minimum inhibitory concentration (MIC) values for agents acting mainly by concentration-depandent mechanisms. It is proposed that pharmacodynamic and population pharmacokinetic data should be integrated through use of the sigmoidal E-max equation, together with mathematical modelling and appropriate statistical analyses, to take account of the natural variation in drug pharmacodynamics and pharmacokinetics. (C) 2000 Elsevier Science B.V. and international Society of Chemotherapy. All rights reserved.
引用
收藏
页码:307 / 313
页数:7
相关论文
共 10 条
[1]  
Aliabadi F. Shojaee, 1997, Journal of Veterinary Pharmacology and Therapeutics, V20, P14
[2]  
Aliabadi F. Shojaee, 1997, Journal of Veterinary Pharmacology and Therapeutics, V20, P48
[3]  
ALIABADI FS, 1996, AVTRW ANN C P, P19
[4]  
[Anonymous], 1999, OP SCI STEER COMM AN
[5]  
Apley MD, 1998, J AM VET MED ASSOC, V212, P1209
[6]   Pharmacokinetics of flumequine in sheep after intravenous and intramuscular administration: Bioavailability and tissue residue studies [J].
Delmas, JM ;
Chapel, AM ;
Gaudin, V ;
Sanders, P .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1997, 20 (04) :249-257
[7]   THE IMPORTANCE OF PHARMACOKINETIC-PHARMACODYNAMIC SURROGATE MARKERS TO OUTCOME - FOCUS ON ANTIBACTERIAL AGENTS [J].
HYATT, JM ;
MCKINNON, PS ;
ZIMMER, GS ;
SCHENTAG, JJ .
CLINICAL PHARMACOKINETICS, 1995, 28 (02) :143-160
[8]  
MARTINJIMENEZ T, J VET PHARM THER, V21, P167
[9]  
Midtvedt Tore, 1998, Microbial Ecology in Health and Disease, V10, P65, DOI [10.1080/089106098435278, DOI 10.1080/089106098435278]
[10]   The use of population pharmacokinetics in drug development [J].
Vozeh, S ;
Steimer, JL ;
Rowland, M ;
Morselli, P ;
Mentre, F ;
Balant, LP ;
Aarons, L .
CLINICAL PHARMACOKINETICS, 1996, 30 (02) :81-93